The oral ghrelin agonist TZP-102 was tested in a phase IIb randomized trial in 201 patients with diabetic gastroparesis. TZP-102 administered at 10 mg or 20 mg daily for 12 weeks had no substantial effect on diabetic gastroparesis symptoms as determined using the Daily Diary of Gastroparesis Symptoms Questionnaire, when compared with patients given placebo. However, a marked symptom improvement was observed in all patients over the trial period.